News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 10, 2021, 02:50 ET Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research ...

Feb 05, 2021, 10:45 ET Orexo calls for redemption of its outstanding bonds and obtains temporary waiver

Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders of the Company's maximum SEK...

Feb 04, 2021, 12:10 ET Orexo has successfully issued senior unsecured callable floating rate bonds

Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable floating rate bonds in the...

Feb 01, 2021, 02:15 ET Orexo contemplates issue of senior unsecured callable floating rate bonds

Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series of fixed income...

Jan 29, 2021, 11:06 ET Orexo expects FDA filing of OX124 mid 2022

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that it is expecting to file its flagship pharmaceutical pipeline asset OX124 with the US ...

Jan 28, 2021, 02:21 ET Orexo Q4 2020, incl. Full Year Report

Q4 2020 highlights Total net revenues of SEK 159.2 m (238.1 last year, 196.2 m excl. Abstral® EU and US) Net earnings of SEK -49.6 m (38.9) EBITDA of ...

Jan 27, 2021, 02:17 ET Orexo strengthens IP rights for overdose rescue drug OX124

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the company has further strengthened the intellectual property (IP) for its flagship ...

Dec 30, 2020, 02:09 ET Orexo announces new US patent for ZUBSOLV®

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®,...

Dec 07, 2020, 02:14 ET Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialisation of...

Nov 16, 2020, 08:39 ET Accenture, Orexo Team to Offer Digital Therapeutics through INTIENT™ Platform

Accenture (NYSE: ACN) has helped the U.S. subsidiary of Swedish pharmaceutical company Orexo launch its first digital therapeutic, vorvida®, for...

Nov 04, 2020, 05:23 ET Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020

(STO:ORX) (OTCQX:ORXOY) In connection with the publication of the Interim Report for Q3 2020, an updated guiding was shared for the full year 2020....

Nov 04, 2020, 02:13 ET Orexo Interim Report Q3 2020

Q3 2020 highlights Total net revenues of SEK 150.3 m (231.2), 189.7 excluding Abstral® EU and US Net earnings of SEK -84.9 m (111.7), net earnings of ...

Oct 15, 2020, 17:23 ET Orexo and Lyfebulb Announce the Winner of the 2020 Innovation Challenge in Substance Use Disorders

Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform,...

Oct 13, 2020, 11:48 ET Orexo´s Nomination Committee for the Annual General Meeting 2021

Prior to the Annual General Meeting (AGM) in 2021, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number ...

Sep 25, 2020, 08:20 ET Invitation - Orexo Digital Therapeutics business update October 1

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts, and media to attend a teleconference on Thursday October 1, at 3 pm...

Sep 14, 2020, 08:02 ET Orexo commences patent infringement litigation against Sun Pharmaceutical

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the...

Sep 09, 2020, 11:14 ET Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options

Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment...

Sep 01, 2020, 08:22 ET Orexo and Lyfebulb Announce the Finalists and Jury for the 2020 Innovation Challenge in Substance Use Disorders

Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform,...

Aug 10, 2020, 02:09 ET Orexo receives paragraph IV Notice Letter for ZUBSOLV® in the US

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical...

Jul 16, 2020, 02:17 ET Orexo Interim Report Q2 2020

Investing in diversification to drive future growth Q2 2020 highlights Total net revenues of SEK 179.1 m (201.2) EBITDA of SEK -9.0 m (60.4),...

Jul 02, 2020, 02:34 ET Orexo Launches Deprexis® and Vorvida® in the US and Provides Updated Financial Guidance

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) announces today the US launch of the scientifically proven digital therapies deprexis® and vorvida®, for...

Jun 30, 2020, 02:28 ET Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE